PE20150465A1 - Sales de un compuesto de benzotiazolona como agonistas del adreno-receptor beta-2 - Google Patents
Sales de un compuesto de benzotiazolona como agonistas del adreno-receptor beta-2Info
- Publication number
- PE20150465A1 PE20150465A1 PE2015000275A PE2015000275A PE20150465A1 PE 20150465 A1 PE20150465 A1 PE 20150465A1 PE 2015000275 A PE2015000275 A PE 2015000275A PE 2015000275 A PE2015000275 A PE 2015000275A PE 20150465 A1 PE20150465 A1 PE 20150465A1
- Authority
- PE
- Peru
- Prior art keywords
- beta
- compound
- adrene
- salts
- receptor agonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A UNA FORMA CRISTALINA DE LA SAL DE ACETATO DEL COMPUESTO (R)-7-(2-(1-(4-BUTOXI-FENIL)-2-METIL-PROPAN-2-IL-AMINO)-1-HIDROXI-ETIL)-5-HIDROXI-BENZO-[d]-TIAZOL-2(3H)-ONA DE FORMULA (I) CUYO PATRON DE DIFRACCION EN POLVO DE RAYOS X EXPRESADOS EN ANGULOS 2-THETA COMPRENDE TRES PICOS QUE TIENEN VALORES SELECCIONADOS DE 8.8 � 0.2�, 16.4 � 0.2� Y 20.8 � 0.2�, CUANDO SE MIDEN UTILIZANDO RADIACION DE CuK alfa. TAMBIEN SE REFIERE A UN PROCESO PARA SU ELABORACION Y A UNA COMPOSICION FARMACEUTICA. DICHO COMPUESTO ES UN AGONISTA DEL ADRENO-RECEPTOR BETA-2 SIENDO UTIL PARA EL TRATAMIENTO DE DISTROFIA MUSCULAR, ATROFIA RELACIONADA CON DESUSO, CAQUEXIA O SARCOPENIA
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IQ23912 | 2012-08-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20150465A1 true PE20150465A1 (es) | 2015-04-22 |
Family
ID=53386469
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2015000275A PE20150465A1 (es) | 2012-08-30 | 2013-08-29 | Sales de un compuesto de benzotiazolona como agonistas del adreno-receptor beta-2 |
Country Status (27)
Country | Link |
---|---|
EP (2) | EP3243817A1 (es) |
KR (1) | KR20150047586A (es) |
CN (2) | CN106146428A (es) |
BR (1) | BR112015004127A2 (es) |
CA (1) | CA2882877A1 (es) |
CL (1) | CL2015000461A1 (es) |
CY (1) | CY1120225T1 (es) |
DK (1) | DK2890687T3 (es) |
EA (1) | EA029946B1 (es) |
ES (1) | ES2642003T3 (es) |
HK (1) | HK1206015A1 (es) |
HR (1) | HRP20171362T1 (es) |
HU (1) | HUE033655T2 (es) |
IL (1) | IL237382A0 (es) |
LT (1) | LT2890687T (es) |
MA (1) | MA37872A1 (es) |
MX (1) | MX351741B (es) |
MY (1) | MY169038A (es) |
NZ (1) | NZ705319A (es) |
PE (1) | PE20150465A1 (es) |
PL (1) | PL2890687T3 (es) |
PT (1) | PT2890687T (es) |
SA (1) | SA515360076B1 (es) |
SG (2) | SG11201501293PA (es) |
SI (1) | SI2890687T1 (es) |
TN (1) | TN2015000058A1 (es) |
WO (1) | WO2014033654A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3192B1 (ar) | 2011-09-06 | 2018-03-08 | Novartis Ag | مركب بنزوثيازولون |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR040962A1 (es) | 2002-08-09 | 2005-04-27 | Novartis Ag | Compuestos derivados de tiazol 1,3-2-ona, composicion farmaceutica y proceso de preparacion del compuesto |
CA2514733A1 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
JP2007537187A (ja) | 2004-05-13 | 2007-12-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 呼吸器疾患の治療においてβアゴニストとして使用するためのヒドロキシ置換ベンゾ縮合ヘテロ環化合物 |
GB0426164D0 (en) * | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
JO3192B1 (ar) * | 2011-09-06 | 2018-03-08 | Novartis Ag | مركب بنزوثيازولون |
AU2014222362B2 (en) * | 2013-02-28 | 2016-07-21 | Novartis Ag | Formulation comprising benzothiazolone compound |
-
2013
- 2013-08-29 NZ NZ705319A patent/NZ705319A/en not_active IP Right Cessation
- 2013-08-29 PT PT138120753T patent/PT2890687T/pt unknown
- 2013-08-29 LT LTEP13812075.3T patent/LT2890687T/lt unknown
- 2013-08-29 SG SG11201501293PA patent/SG11201501293PA/en unknown
- 2013-08-29 MA MA37872A patent/MA37872A1/fr unknown
- 2013-08-29 ES ES13812075.3T patent/ES2642003T3/es active Active
- 2013-08-29 PL PL13812075T patent/PL2890687T3/pl unknown
- 2013-08-29 MY MYPI2015000453A patent/MY169038A/en unknown
- 2013-08-29 SI SI201330750T patent/SI2890687T1/sl unknown
- 2013-08-29 EP EP17171708.5A patent/EP3243817A1/en not_active Withdrawn
- 2013-08-29 EP EP13812075.3A patent/EP2890687B1/en active Active
- 2013-08-29 HU HUE13812075A patent/HUE033655T2/en unknown
- 2013-08-29 DK DK13812075.3T patent/DK2890687T3/en active
- 2013-08-29 PE PE2015000275A patent/PE20150465A1/es not_active Application Discontinuation
- 2013-08-29 WO PCT/IB2013/058109 patent/WO2014033654A1/en active Application Filing
- 2013-08-29 SG SG10201704377PA patent/SG10201704377PA/en unknown
- 2013-08-29 EA EA201590452A patent/EA029946B1/ru not_active IP Right Cessation
- 2013-08-29 CN CN201610537241.9A patent/CN106146428A/zh active Pending
- 2013-08-29 MX MX2015002656A patent/MX351741B/es active IP Right Grant
- 2013-08-29 KR KR1020157007573A patent/KR20150047586A/ko not_active Application Discontinuation
- 2013-08-29 CA CA2882877A patent/CA2882877A1/en not_active Abandoned
- 2013-08-29 BR BR112015004127A patent/BR112015004127A2/pt not_active Application Discontinuation
- 2013-08-29 CN CN201380055093.1A patent/CN104736525B/zh not_active Expired - Fee Related
-
2015
- 2015-02-20 TN TNP2015000058A patent/TN2015000058A1/fr unknown
- 2015-02-23 IL IL237382A patent/IL237382A0/en unknown
- 2015-02-25 CL CL2015000461A patent/CL2015000461A1/es unknown
- 2015-02-26 SA SA515360076A patent/SA515360076B1/ar unknown
- 2015-07-08 HK HK15106522.7A patent/HK1206015A1/xx not_active IP Right Cessation
-
2017
- 2017-09-11 HR HRP20171362TT patent/HRP20171362T1/hr unknown
- 2017-09-13 CY CY20171100967T patent/CY1120225T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
LT2890687T (lt) | 2017-09-11 |
NZ705319A (en) | 2018-05-25 |
PT2890687T (pt) | 2017-10-05 |
BR112015004127A2 (pt) | 2017-07-04 |
HRP20171362T1 (hr) | 2017-11-03 |
CN104736525B (zh) | 2016-08-24 |
SG11201501293PA (en) | 2015-03-30 |
MX351741B (es) | 2017-10-26 |
KR20150047586A (ko) | 2015-05-04 |
SI2890687T1 (sl) | 2017-10-30 |
CN104736525A (zh) | 2015-06-24 |
TN2015000058A1 (en) | 2016-06-29 |
PL2890687T3 (pl) | 2017-11-30 |
MY169038A (en) | 2019-02-07 |
EA201590452A1 (ru) | 2015-07-30 |
MX2015002656A (es) | 2015-05-20 |
ES2642003T3 (es) | 2017-11-14 |
EP3243817A1 (en) | 2017-11-15 |
HUE033655T2 (en) | 2017-12-28 |
HK1206015A1 (en) | 2015-12-31 |
SA515360076B1 (ar) | 2016-03-20 |
EA029946B1 (ru) | 2018-06-29 |
IL237382A0 (en) | 2015-04-30 |
WO2014033654A1 (en) | 2014-03-06 |
SG10201704377PA (en) | 2017-06-29 |
DK2890687T3 (en) | 2017-10-09 |
CL2015000461A1 (es) | 2015-05-04 |
EP2890687B1 (en) | 2017-06-28 |
MA37872A1 (fr) | 2018-07-31 |
CA2882877A1 (en) | 2014-03-06 |
EP2890687A1 (en) | 2015-07-08 |
CY1120225T1 (el) | 2018-12-12 |
CN106146428A (zh) | 2016-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY35683A (es) | Polimorfo de inhibidores de tirosina quinasa de bazo (syk) | |
BR112015006075A2 (pt) | composto cristalino, composição farmacêutica, uso do composto cristalino, hidrato cristalino do bromidrato de vortioxetina, método para a preparação do hidrato cristalino de bromidrato de vortioxetina, método para a preparação do composto cristalino e uso do hidrato cristalino de bromidrato de vortioxetina | |
CR20160099A (es) | Formulación de inhibidores de la syk | |
MX2015011273A (es) | Uso de derivados de pirazolopirimidina para el tratamiento de trastornos relacio nados con la fosfoinositida 3-cinasa delta. | |
UY35590A (es) | Nuevos compuestos para el tratamiento del cáncer | |
BR112014029530A2 (pt) | compostos, composição farmacêutica e uso de um composto | |
DK2827710T3 (da) | Doseringsskema for echinocandin-klasse-forbindelser | |
BR112016011065A2 (pt) | Composto cristalino, composição farmacêutica, forma de dosagem, método para tratar anemia | |
HU1000069D0 (en) | New salts for the preparation of pharmaceutical composition | |
BR112015007310A2 (pt) | compostos, composição farmacêutica, uso de um composto de fórmula (i) e uso de uma composição farmacêutica | |
AR107548A1 (es) | Forma cristalina a de agonista de tlr7, su proceso de preparación y uso | |
CR20150245A (es) | Proceso novedoso para la elaboración de compuestos para uso en el tratamiento de cáncer | |
BR112015031619A2 (pt) | forma cristalina estável de cloridrato de tipiracil e método de cristalização para a mesma | |
BR112014006420A2 (pt) | compostos, composição farmacêutica, uso de um composto e mètodo para o tratamento ou profilaxia | |
PT3541814T (pt) | Compostos de amino-naft[1,2-d]imidazol-5-ona 2-substituída ou seus sais farmaceuticamente aceitáveis | |
BR112012029226A2 (pt) | processo para a preparação de um composto quiral, composto quiral cristalino, sal de hcl do composto quiral cristalino, composto quiral e uso do composto | |
EP2736905A4 (en) | INTERMEDIATE COMPOUNDS AND PROCESS FOR THE PREPARATION OF LURASIDONE AND SALTS THEREOF | |
CR20140325A (es) | Nuevos derivados de morofolinilo útiles como inhibodores de mogat-2- | |
MX2015012318A (es) | Formas de estado solido de un derivado de quinazolina y su uso como un inhibidor de braf. | |
CL2015001881A1 (es) | Compuesto 4-hidroxi-2-metil-5-(propan-2-iliden)ciclohexil-3-en-1-carbaldehido; uso del compuesto para el tratamiento de la enfermedad de alzheimer; composición farmacéutica; método para preparar la composición. | |
BR112014001425A2 (pt) | forma de dosagem farmacêutica, composição farmacêutica, e, composto (i) ou sal farmaceuticamente aceitável do mesmo | |
HK1198514A1 (en) | Substituted heterocyclic compounds for disease treatment | |
UA111334C2 (uk) | Дельта-кристалічна форма аргінінової солі периндроприлу, спосіб її одержання і фармацевтична композиція, яка її містить | |
PE20150465A1 (es) | Sales de un compuesto de benzotiazolona como agonistas del adreno-receptor beta-2 | |
PH12015501701A1 (en) | Formulation comprising benzothiazolone compound |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application declared void or lapsed |